Imunon Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Imunon's earnings are forecast to decline at 19.6% per annum while its annual revenue is expected to grow at 82.9% per year. EPS is expected to grow by 36% per annum.

Wichtige Informationen

-19.6%

Wachstumsrate der Gewinne

36.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum37.3%
Wachstumsrate der Einnahmen82.9%
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

Low

Zuletzt aktualisiert31 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

LSE:0HUZ - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/2026N/A-35-45-464
12/31/2025N/A-27-37-344
12/31/2024N/A-22-29-294
6/30/2024N/A-18-19-19N/A
3/31/2024N/A-19-21-21N/A
12/31/2023N/A-20-19-19N/A
9/30/20230-28-21-20N/A
6/30/20230-31-21-20N/A
3/31/20230-31-19-19N/A
12/31/20221-36-23-23N/A
9/30/20221-27-23-23N/A
6/30/20221-26-23-22N/A
3/31/20221-26-20-19N/A
12/31/20211-21-17-16N/A
9/30/20211-20-15-15N/A
6/30/20211-22-15-15N/A
3/31/20211-22-16-15N/A
12/31/20201-21-16-16N/A
9/30/20201-22-18-18N/A
6/30/20201-19-18-18N/A
3/31/20201-20-20-20N/A
12/31/20191-17-21-20N/A
9/30/20191-8-9-9N/A
6/30/20191-7-9-8N/A
3/31/20191-10-8-8N/A
12/31/20181-12-7-7N/A
9/30/20181-22-17-17N/A
6/30/20181-23-18-18N/A
3/31/20181-20N/A-18N/A
12/31/20171-21N/A-17N/A
9/30/20171-21N/A-17N/A
6/30/20171-22N/A-17N/A
3/31/20171-21N/A-17N/A
12/31/20161-22N/A-18N/A
9/30/20161-22N/A-18N/A
6/30/20161-20N/A-18N/A
3/31/20161-21N/A-20N/A
12/31/20151-22N/A-21N/A
9/30/20151-23N/A-23N/A
6/30/20151-26N/A-24N/A
3/31/20151-27N/A-22N/A
12/31/20141-25N/A-21N/A
9/30/20141-23N/A-18N/A
6/30/20141-20N/A-15N/A
3/31/20141-13N/A-16N/A
12/31/20131-13N/A-10N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 0HUZ is forecast to remain unprofitable over the next 3 years.

Ertrag vs. Markt: 0HUZ is forecast to remain unprofitable over the next 3 years.

Hohe Wachstumserträge: 0HUZ is forecast to remain unprofitable over the next 3 years.

Einnahmen vs. Markt: 0HUZ is forecast to have no revenue next year.

Hohe Wachstumseinnahmen: 0HUZ is forecast to have no revenue next year.


Wachstumsprognosen für den Gewinn je Aktie


Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if 0HUZ's Return on Equity is forecast to be high in 3 years time


Wachstumsunternehmen entdecken